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objectives 
After completing this module students and public health 
professionals should:  
• Increase their knowledge related to the concept of Disease 
management programmes (DMPs); 
• Know some examples of different DMPs; 
• Recognize the basic principles in the implementation of a 
DMP; 
• Understand the basic features of a DMP; and 
• Identify different approaches and technologies in DMP 
implementation. 
Abstract At present almost all health care systems are concerned mainly 
with ensuring equity, access, high quality and efficiency of 
health care. A very important aspect of quality, especially in 
public health, is its relation to scientific knowledge about 
effective interventions. The concept of Disease management 
programmes (DMPs) has been introduced to implement 
evidence-based clinical practice through guidelines, care 
protocols etc, to improve coordination among healthcare 
providers and assure continuity and comprehensiveness of care. 
DMPs organize health care in multidisciplinary, 
multicomponent, proactive approach focusing on the whole 
course of a disease, using evidence-based standards of care. 
There is no single definition of a Disease management 
programme, because of their diversity and heterogeneity. They 
are characterized by three main features: a knowledge base, a 
delivery system with coordinated care components, and a 
continuous improvement process. The basic advantages and 
uncertainties about DMPs are discussed in the module, as well as 
the ways and results of their implementation. A case study is 
presented, discussing a proposed model for Cardiovascular 
disease management programme in Bulgaria.  
Teaching 
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for teachers 
• Work under teacher supervision/individual students’ work 
proportion: 30%/70%; 
• Facilities: computer room 
• Equipment: computers, LCD projection equipment, internet 
connection, access to bibliographic data-bases; 
• Training materials: recommended readings or other related 
readings; 
• Target audience: master degree students according to Bologna 
scheme. 
Assessment of 
students 
Assessment should be based on the group-work, seminar papers, 
and case-problem presentations. 
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THEORETICAL BACKGROUND 
Disease Management Programs (DMPs) 
In the last decade health care systems across the world are concerned mainly with few 
questions: continuity of care, especially for chronic diseases; avoidance of medical errors 
and patient safety; effective and efficient delivery of health services; and avoiding 
excessive variations in practice (1). Most of the countries in the World Health Organization 
European Region have implemented national strategies for quality assurance, such as 
accreditation systems, hospital quality management or external assessments such as league 
tables or audits (2,3). A very important aspect of quality, especially in public health, is its 
relation to scientific knowledge about effective interventions. High quality care can be 
achieved only when interventions that work are applied to the right patients at the right 
time (4). Improving quality of medical care and health services is thus a matter of defining 
and promoting best clinical practice, translating evidence from research into practical 
work, namely developing evidence-based guidelines, or recommendations, and performing 
health technology assessment. Quality of health care delivery is not, however, only a 
matter of evidence-based practice. Organizational and structural aspects of the health 
system and delivery also have important implications. A lack of continuity of care may 
delay appropriate measures, duplicate services, and lead to uncoordinated interventions (5). 
The concept of Disease management programs (DMPs) has been introduced to 
implement evidence-based clinical practice through guidelines, care protocols, and 
formulary lists, improve coordination among healthcare providers and assure continuity 
and comprehensiveness of care (6). DMPs organize health care in multidisciplinary, 
multicomponent programs, in a proactive approach focusing on the whole course of a 
disease, using evidence-based standards of care (5). There is no single definition of a 
disease management programme, however, it is characterized by three main features: a 
knowledge base, a delivery system with coordinated care components, and a continuous 
improvement process (7).  
The key elements of disease management are (6): 
− Comprehensive care: multiprofessional, multidisciplinary, combining acute and long-
term care, disease prevention and health promotion; 
− Integrated care – “continuum of care”, coordination of the different components of 
the health services delivery; 
− Population orientation - defined by a specific condition; 
− Active client-patient management tools - health education, empowerment, self-care; 
− Evidence-based guidelines, protocols, care pathways / DRGs; 
− Information technology & system solutions; 
− Continuous quality improvement. 
 
DMP represents a total management of disease and health services, as a method for 
development of active consensus in the State, mobilizing different stakeholders and 
responsible institutions in order to fulfil the health priorities set. It is not a legal act or  
administrative document, but rather a comprehensive National Strategy, requiring 
professionalism, systematic and integral approach, characterized by (8): 
− Solidarity and justice in the health system; 
− Universal access to medical services; 
− High quality and continuity of health care; 
− Effectiveness and efficiency of health services; 
− Horizontal and vertical management of the planned interventions; 
− Decentralization and multi-sectoral partnership. 
 
Following these basic principles of the New Public Health (9) is a governmental 
responsibility on the way to reach the final goal and priority of any health system – 
promotion and protection of population health and strengthening the human capital of the 
country. 
 In this context, the management of any disease is realized through coordinated and 
integrated care, focused on the entire pre-clinical and clinical development of the disease: 
early diagnosis, treatment and rehabilitation, as well as towards health promotion and 
disease prevention through reduction of risk factors levels in the living environment, 
introduction of healthy behaviours and lifestyle, and increasing the quality and 
effectiveness of medical services.  
The DMP is a broad term, comprising of various methods, forms of interventions, 
organizational approaches and technologies. They are very heterogeneous, consisting of 
diverse, sometimes unique components, developed for specific demographic, health, social, 
economic, political, or cultural settings. Considering this, it is completely impossible to 
create a unified model of a DMP or to translate it to another national context. The basis for 
the development of a nationally specific and effective DMP is the correlation “population 
necessities – available resources”. This is a difficult and responsible analysis, requiring a 
multidisciplinary team, which should consider (8): 
− The health needs and necessities of certain (entire / target) population and the 
society; 
− The specific methodology of programme development (goal, stages, control etc); 
− The provision of recourses for the programme – mainly financial, human, 
information; 
− The effective management of the resources; 
− The coordination of all participants in the programme – individuals and institutions; 
− The monitoring, control and evaluation of the DMP; and 
− The capacity for sustainability and improvement of the programme for a long-term 
period. 
 
Critical factors in the design of a successful DMP (5): 
− suitable target condition (target population); 
− evidence base (relevant scientific research); 
− consideration of barriers to implementation; 
− strategies to change attitudes of stakeholders; 
− balance of economic and quality of care goals; 
− strategies for continuous quality improvement; and 
− strategies for evaluation of cost-effectiveness. 
Implementation of DMPs for total management of chronic diseases 
Chronic diseases and especially cardiovascular diseases (CVD) account for most of the 
burden of disease in the European Region (10). Recent evidence shows that there is a 
strong need to improve the quality of care for people with chronic diseases. Although a 
number of effective interventions for management of various chronic conditions are 
promoted by the international health organization, there are still wide variations in the 
delivery of care and clinical practice. DMPs are one of the measures intended to address 
this situation. Most of the evaluated DMPs for chronic conditions have been shown to 
improve the management and control of the disease, namely diabetes, depression, chronic 
heart failure and cardiovascular diseases (5). The evidence from the implemented till now 
DMPs in different countries and settings can be summarized in the following conclusions 
(11): 
− DMPs seem to be suitable for conditions for which there are wide practice variations 
and poor outcomes, due to problems in continuity of care and finding evidence of 
interventions’ effectiveness;  
− DMPs reach a better control of the underlying condition, mostly for CVD, shown by 
reducing the risk of hospitalization among heart disease patients; 
− Improved rates of medical performance suggest that DMPs succeed in shifting care 
from a reactive approach (reacting to manifest complications) to a proactive one 
(anticipating potential complications); 
− DMPs enhance the adherence of providers to evidence-based standards, as well as 
enhance continuity of care and improve patients’ knowledge of their 
condition/illness; 
− In defining the goal(s) of a DMP it is important to achieve a balance between quality 
of care, satisfaction of providers and patients, and cost; 
− Disease management requires behavioural changes in both providers and patients; 
− A system of performance and outcomes indicators is considered an essential 
component of a DMP to ensure its continuous quality improvement; 
− The disease management approach needs to have a long-term perspective; 
− No evidence is available for any recommendation about the ideal mix of 
interventions; 
− No evidence is available about which components of a DMP are most important for 
improving quality of care; 
− There is no evidence of a direct link between DMPs and significant reduction in 
mortality or of improvement in quality of life; 
− There is no evidence available about long-term health outcomes; 
− There is no evidence on cost-effectiveness of DMPs. 
 
However, the absence of evidence does not mean absence of the effect; it means it 
has not been studied. The strong focus on a particular disease, risk factor or symptom has 
also been claimed to be one of the possible negative effects of DMPs, however there is no 
evidence for this. The long-term impact of DMPs on health and health care systems still 
needs to be evaluated. The impact of DMPs on patients’ and providers’ satisfaction also 
remains to be assessed (5).  
 
 
Cost and cost-effectiveness of DMPs for chronic conditions 
When DMPs were introduced for the first time in the United States, their primary goal was 
to achieve cost savings (12). The implementation of DMPs requires substantial  
investments. The cost of developing and establishing a program, including training and 
information technologies (especially hardware and software), needs to be considered in 
evaluations of disease management (6). The available evidence about reduced episodes of 
hospitalization and reduced rates of complications from chronic disease have been claimed 
to be potentially cost-saving. However, there is not enough evidence to conclude that 
DMPs are more cost-effective than standard care. Another important gap relates to the 
ideal allocation of resources to the different components of a programme. Therefore it is 
important to study extensively the cost-effectiveness of any specific DMP and its 
components before it is introduced on a large-scale. 
 
 
Potential ethical considerations 
Concerns have been raised about the ethical and social implications of DMPs (6). Patient 
autonomy might be threatened by the reduction of freedom of choice resulting from 
standardization. It is also necessary to identify who should play the coordinating role in a 
DMP, and what implications this may have for the responsibilities of others (6). Many 
DMPs have been developed with the assistance of commercial interests, notably the 
pharmaceutical industry. Concerns have been expressed about potential conflicts of interest 
in the health care system (13,14).  
 
 
Conclusions (5) 
The organization of care in multidisciplinary, multicomponent programmes, with a 
proactive approach focusing on the whole course of a chronic disease, applying the ideas 
of evidence-based medicine for the formulation of standards of care, can be considered the 
core of DMPs. 
The heterogeneity of DMPs and their dependence on context, complicate the 
transferability of findings to other settings other than those of their evaluation. There is no 
single DM model to be applied everywhere. It is not possible to identify an ideal mix of 
components for a DMP to be effective. 
DMPs improve the quality of care of people with chronic diseases, as measured by 
performance indicators. However, there is no evidence available on DMPs’ impact on 
survival, quality of life or on their relative cost-effectiveness. 
There is a need to evaluate the economic, social and ethical implications of disease 
management programmes. 
 
 
Examples of ongoing DMPs in Europe 
Maastricht Project (15): In January 2000 a DMP for patients with diabetes was 
implemented in the Maastricht region in The Netherlands. The explicit aim is to improve 
the quality of care for patients with diabetes. The programme’s elements are: a core team 
of general practitioners, nurse specialists and endocrinologists; cooperation with other 
caregivers (e.g. ophthalmologists, dieticians); protocols stating routes of care, 
responsibilities and tasks; provision of care according to clinical practice guidelines; and 
systematic collection of data about patient contacts in order to monitor each patient and 
assess practice variations among providers.  
National Service Frameworks in the United Kingdom (16): the 1997 Government 
White Paper set out the plan for the modernization of the British NHS. As a result, 
National Service Frameworks (NSFs) have been established by the NHS to enhance the 
quality and efficiency of the system. Strictly speaking, the NSFs are not DMPs; however, 
they represent a systematic effort to improve care for particular conditions or groups of 
patients, and share some elements of disease management. They approach the whole 
course of a condition and the state’s comprehensive strategies to organize care with the aim 
of improving outcomes. The NSFs set national evidence-based standards of care, including 
organizational interventions, formulate service delivery strategies and establish 
performance measures to evaluate progress.  
 German Disease Management Programmes (5): the health care reform act from 
2001 provided the basis for the implementation of DMPs in Germany. The programmes are 
offered by the health funds must be accredited by the Federal Insurance Office, a 
governmental agency charged with the supervision of social insurances. Implementation of 
DMPs is linked to financial incentives for the health funds, as enrolled patients are 
calculated separately in the inter-sickness fund risk compensation mechanism. Evidence-
based minimum standards and criteria for enrolment are proposed by the Coordinating 
Committee (a self-governing body including sickness funds and providers representatives) 
and subsequently passed by the Ministry of Health and Social Security. 
 
 
CASE STUDY 
Cardiovascular disease management programme – the case of 
Bulgaria 
Introduction and background 
Cardiovascular morbidity and mortality – present situation and trends 
Bulgaria takes one of the leading positions in total and CVD mortality in the European 
Region and the negative tendencies are continuing in the last 15 years. Cardiovascular 
diseases are causing 971.0 per 100000 deaths for 2007 or more than 66% of the total 
mortality (17). The CVD indicators, as hospital discharges of ischemic heart disease per 
100000 – 857.48 for 2006 and of cerebrovascular diseases per 100000 – 617.94 for 2006 
are also disturbing (18). The results from the largest national epidemiological studies, 
conducted in the last 20 years “Sofia Heart Study 1994 - 1999”, “Bulgaria Heart Study 
1998” as well as the results from the CINDI programme show evidence of higher levels of 
preventable risk factors and higher individual and population absolute risk, compared to 
other European countries (19). These negative trends are considered mostly a result from 
recently developed unhealthy lifestyles and behaviours, related to the transition period, but 
also from the continuing and unsuccessful health care reform (started in 2000), leading to 
insufficient disease prevention, late diagnoses, ineffective treatment, low compliance of 
physicians to international guidelines and of patients to recommended therapy and lifestyle 
changes (20). At the same time, hospital mortality from Acute Myocardial Infarction is 
close and even lower than some European hospitals, which indicates that the qualification 
of specialists, especially in hospital care are still on a good level (21). The pointed facts as 
well as evidence from other relevant studies, allow for the following assumptions (22): 
− Low quality and effectiveness of the Primary care (GPs), especially when concerning 
the level of qualification, organization, motivation for improvement, compliance to 
contemporary best practices and implementation of health promotion and disease 
prevention activities; 
− Ineffective Emergency care, related to lack of financial, material and human 
resources; 
 − Insufficient personal responsibility, information and motivation for self-control and 
self-management of the health status; 
− Insufficient state and public responsibility for introduction of evidence-based, 
equitable and effective health care; 
− Continuing organizational problems and chaotic reforms in the health care system, 
characterized by: 
• Lack of managerial and governance capacity; 
• Lack of integrated information system and chronic disease registries; 
• Lack of working system for quality assessment and control; 
• Inefficient allocation of financial resources; 
• Insufficient official standards and guidelines for good medical practice; 
• Lack of incentives for the health providers; and 
• Lack of trust in the population. 
 
Activities, undertaken to address the problem 
Bulgaria is still waiting for its new National Health Strategy (last one adopted in 2001) and 
for a National strategy for prevention and control of chronic (including CVD) diseases. In 
2001, the Government adopted a programme, called “Bulgaria 2001”, where a “National 
programme for control of cardiovascular diseases” was announced (23). No specific action 
plan, activities or any results have been published under it till the present moment. 
However, there are single legal orders and risk factor control programmes adopted (for 
example, against smoking, diabetes control etc). Bulgaria is also participating in the 
International intervention programme for integrated chronic noncommunicable diseases 
prevention - CINDI programme (24). The National Centre for Public Health Protection has 
recently published the “WHO CVD-risk management package for low- and medium-
resource settings, 2002”, translated in Bulgarian (25).  
Prevention activities and published guidelines: 
1. Establishment of a National Committee for development of guidelines for clinical 
practice of general practitioners (GPs), 2006 with members from Bulgarian scientific 
society for general practice, the National association of the GPs in Bulgaria and the 
Bulgarian Hypertension League; 
2. Start of a permanent CME course for high blood pressure and cardiovascular risk 
education - "Educational Master Course on Hypertension and Cardiovascular Risk”, 
European Society of Hypertension (ESH) / Bulgarian Hypertension League (BHL) - 
2006, 2007, 2008; 
3. Translation / development and publishing of: 
− ESH / ESC guidelines, 2003, 2007 – full and pocket versions are translated, 
adopted and published by the BHL / BSC; 
− Consensus for mono- and combination therapy of high blood pressure, BSC, 
2005;  
− Guidelines for assessment and control of high blood pressure, 2006;  
− Practical recommendations for management of high blood pressure, according 
to the ESH/ESC guidelines, 2007; 
− Guidelines (handbook) for general practitioners in the case of high blood 
pressure, 2007;  
− Information and education materials – leaflets, brochures, books for the patient. 
 Nevertheless, there are no officially adopted Medical Standards for cardiovascular 
prevention and treatment; there are no effective mechanisms and incentives to motivate the 
health care providers to follow the published recommendations and not enough public 
educational programmes. 
Based on the analysis of the available European and national epidemiologic and 
other studies, a comprehensive, evidence-based national cardiovascular disease 
management programme has been developed. Here its basic components are presented 
without any detailed explanations or activities. 
 
 
 Strategic (long-term) goal: 
Decrease the CVD incidence and mortality, increase the quality of life of CVD patients 
and the healthy life expectancy (HALEs) in the Bulgarian population. 
 
 
 Operational (short-term) goal:  
Successful implementation of a cardiovascular disease management programme and 
development of a national evidence-based, long-term Strategy for chronic disease control 
and prevention in Bulgaria. 
 
Programme objectives: 
− Health promotion and CVD risk factor prevention; 
− Early detection and treatment of underlying risk factors; 
− Early diagnosis and treatment of CVD; and  
− Secondary and tertiary prevention of CVD. 
 
 
  Leading principles of the programme: 
− Chronic noncommunicable diseases and especially CVD should become a priority 
for the national health policy; 
− The main responsibility should be taken by the government, but decisions and 
activities should be multi-sectoral, multi-level, including all policies and spheres; 
− Strong state control and regulation of health determinants and threats; 
− Strict prioritization and control in financing and subsidizing; 
− Specific capacity building in health care, focused on long-term care of chronic 
conditions; 
− Continuous adaptation and improvement of the health system and increasing quality 
and effectiveness of care, 
− Consistent policy for making healthy choices - easier choices; 
− Implementation of evidence-based interventions, related to population necessities 
and national specificity; 
− Early, continuous and life-long risk factor and disease prevention and health 
promotion; 
− Increasing personal responsibility for health – “personal empowerment”; 
− Strong public participation, social commitment and support for health – “social 
empowerment”; and 
− Development and setting up of “healthy public policy” – health in all policies. 
  Intervention spheres (groups): 
− Surrounding environment (political, social, economic and ecological) – 
environmental protection, social inequalities etc; 
− Individual (personal health protection) – behaviour, knowledge, skills, motivation, 
lifestyle; 
− Population free of disease (risk management) – detection and control of risk factors; 
− Patients: 
• with acute CVD (clinical management) – emergency care, treatment and 
rehabilitation; 
• with chronic CVD (clinical management and social integration) – long-term 
care, disability rehabilitation, social support etc.; 
• high risk groups (potential patients). 
 
 
 Intervention approaches: 
− Political interventions and lobbying for health; 
− Intensive health information and education; 
− State regulation and increased priority financing; 
− Capacity building in public health; 
− Improvement of health services delivery - integrated and patient-cantered care; and 
− Public participation and partnership. 
 
 
Structural elements of the programme, according to health system 
levels 
 Macro-level: development of positive political setting: 
− Leadership and political will for healthy public policy; 
− Integration and partnership between different policies; 
− Provision of sustainable financing; 
− Priority distribution of human resources – introduction of a health map; 
− Legal changes and regulations; and 
− Intensive multi-sectoral approach. 
 Intermediate level: 
− Health system organization: 
• Ensuring continuity and coordination of medical services and life-long care; 
• Increasing quality of care through various incentives; 
• Organization and equipment of multi-professional health teams in Primary 
care; 
• Stimulation of self-control, self-management and prevention; and 
• Implementation of information systems and registries. 
− Public participation and support: 
• Increasing public awareness and opposition of stigmatization; 
• Stimulation of positive results through moral and material incentives; and 
• Provision of additional health and social services. 
 Micro-level: relationship with the individual (patient): 
− Information, education and motivation of the patients and their families; 
− Information, education and motivation of the health providers; and 
− Information, education and motivation of the social partners. 
 
 
 Participants in the programme: 
 Central (macro-) level: 
− Government, Higher Medical Council; 
− Parliament (Commission on health); 
− Ministry of health (MH) in collaboration with all other Ministries; 
− National centre for public health protection; 
− National centre for health information; 
− National health insurance fund (NHIF); 
− Professional organization s of physicians (BMA), dentists and pharmacists; 
− Medical and public health schools; and 
− Different NGOs –agencies, associations etc. 
 
 Intermediate level: 
− Regional offices / branches of the MH, NHIF, BMA etc; 
− Medical establishments – managerial level; 
− Voluntary health insurance funds; 
− Media; 
− Professional organizations of medical specialists (Bulgarian Society of Cardiology, 
Bulgarian Hypertension League, Bulgarian Lipid League etc); 
− NGOs (patients’ associations, syndicates, foundations etc); and 
− The Industry (pharmaceutical, food and beverages, sports and leisure etc). 
 
 Peripheral (micro-) level: 
− Health professionals – physicians, nurses etc; 
− Other professionals working in health care – economists, lawyers, psychologists, 
social workers etc; 
− Professionals, related to the population and individual health – teachers, sociologists 
etc. 
 
 
 Stages in the DMP implementation: 
 I stage – preparation (~ 1 year): activities for planning, coordination and 
organization of the programme implementation and setting up an Action plan; 
 II stage – implementation (~ 3 years): realization of the particular activities and 
interventions, according to the Action plan and monitoring of their effectiveness; 
 III stage – final (~ 1 year): analysis and evaluation of the results, achieved and 
development of Action plan for the next period. 
 
 
 Monitoring and performance indicators 
In order to improve dynamically the programme and its interventions periodic analyses 
should be performed and feedback received. Some of the possible indicators are: total risk 
assessment of representative sample of the population, CVD incidence trends during the 
period, level of patients’ compliance and adherence, patients’ satisfaction, behavioural or 
attitude change, etc. 
  Expected results 
 Some of the specific results to be expected from the proposed programme are: 
− Better coordination, continuity and effectiveness in the health sector: 
• Better risk assessment and detection of high risk groups for CVD; 
• Better control and prevention of risk factors; 
• Better treatment and rehabilitation of CVD patients; 
• Implementation of evidence-based standard protocols, guidelines and 
recommendation for good clinical practice; 
• Increased motivation and compliance of health specialists. 
 
− Decrease in the CVD incidence; 
− Increased economic effectiveness and efficiency; 
− Development of a National register for CVD diseases; 
− Increased health awareness and culture of the population; 
− Increased social participation and commitment; 
− Decreasing inequalities in health etc. 
 
 
 Financial sources for the programme: 
− The Government and Ministry of health, NCPHP; 
− Municipalities; 
− NGOs (foundations, associations etc); 
− The Industry and other business etc. 
 
 Conclusion 
The problem of cardiovascular diseases in Bulgaria can be only addressed by means of 
complex, long-term and comprehensive approach, including short-term and long-term 
interventions in the framework of a National Programme (Strategy) for management of 
CVD (26). It cannot be solved through temporary one-sided activities. All interested 
stakeholders and institution should participate in the programme implementation and 
analysis.  
 
 Discussion and possible restrictions of the model 
The proposed programme does not claim to be cost-effective or cost-saving, as clear 
evidence for this is lacking. It is also important to point out that this DMP of CVD does not 
include all possible approaches, interventions and activities for reaching the final goal of 
the programme. This is only a model, an example of a comprehensive evidence-based 
DMP for CVD. 
 
 
 EXERCISES 
 Task 1 
The students are asked to figure out significant public health problems for their country 
(individual work). Then, in an open discussion, together priorities are set up, according to 
the specific national settings. 
  Task 2 
The students are dividing into groups of 3 to 5. every group chooses a priority problem and 
develops a design of a DMP. The models are presented before all students and a discussion 
about their strengths and weaknesses is initiated. 
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